Last reviewed · How we verify
NCT03435120: CAVIDIOM
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
trial testing No intervention in Breakthrough Pain in 118 participants. Completed in 14 February 2020.
24 January 2020
Quick facts
| Lead sponsor | Angelini Farmacéutica |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 118 |
| Start date | 21 December 2017 |
| Primary completion | 24 January 2020 |
| Estimated completion | 14 February 2020 |
| Sites | 14 locations across Spain |
Drugs / interventions tested
- No intervention
Conditions studied
- Breakthrough Pain — all drugs for Breakthrough Pain →
Sponsor
Angelini Farmacéutica
Who can join
18 and older, any sex, with Breakthrough Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment. Moreover, despite the optimal management of basal chronic pain, 66% of these patients have reported breakthrough pain which has a severe impact on quality of life. There is insufficient clinical information on the quality of life of cancer patients with breakthrough pain treated in medical oncology services according to routine clinical practice. For this reason we consider it is appropriate to prospectively evaluate the quality of life of cancer patients with cancer breakthrough pain in medical oncology services as well as other factors that can affect quality of life. This post-authorization observational study will assess the quality of life of cancer patients with breakthrough cancer pain treated in medical oncology services in Spanish hospitals.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03435120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Breakthrough Pain
Currently open trials in the same condition.
- NCT04011150 — Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour · Phase 3 · recruiting
- NCT02278601 — Comparison of Regimens MPIB, CIPCEA, PCEA · Phase 3 · active not recruiting
Other Angelini Farmacéutica trials
Trials by the same sponsor.
- NCT04742413 — A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in · terminated
- NCT04485676 — Dalbavancin in Real Clinical Practice in Spain · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03435120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Angelini Farmacéutica
- Last refreshed: 2 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03435120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing